Researchers have identified N4BP2, an enzyme responsible for chromothripsis, a chaotic chromosome-shattering event prevalent in approximately one in four cancers, as reported by sciencedaily on February 16, 2026. This groundbreaking discovery by scientists at the University of California San Diego sheds new light on how tumors rapidly adapt and resist therapy.
Chromothripsis involves a single catastrophic event where a chromosome breaks into numerous fragments and is then haphazardly stitched back together, according to news-medical. This dramatic genetic reshuffling allows cancer cells to evolve at an accelerated pace, making them particularly challenging to treat.
The enzyme N4BP2 specifically breaks apart DNA that becomes trapped within tiny cellular structures called micronuclei, initiating this genomic destruction, as detailed by UC San Diego Today. Crucially, blocking N4BP2 significantly reduced this DNA damage in laboratory cancer cells, offering a promising new avenue for intervention.
This rapid genetic change, driven by N4BP2, enables tumors to quickly develop resistance to existing treatments, according to sciencedaily. Instead of gradual mutations, chromothripsis creates a burst of genetic alterations, making tumors harder to control.
Cancers exhibiting higher N4BP2 activity also showed increased levels of extrachromosomal DNA (ecDNA), which is strongly linked to aggressive growth and therapy resistance, SSBCrack News confirmed. The findings suggest ecDNA is a direct consequence of chromothripsis, positioning N4BP2 as a critical upstream regulator.
The identification of N4BP2 provides a potential new therapeutic target for some of the most aggressive cancers, sciencedaily reported. Senior author Don Cleveland, Ph.D., stated that targeting N4BP2 could limit the genomic chaos that allows tumors to adapt and recur.
-
Chromothripsis, meaning "chromosome shattering," was first recognized over a decade ago as a major driver of cancer progression, involving extensive chromosome fragmentation and random reassembly, as noted by Biotechnology Kiosk. This catastrophic event differs significantly from the slow accumulation of mutations typically associated with cancer development.
-
The mechanism often initiates when errors during cell division cause chromosomes to become isolated within fragile micronuclei, according to UC San Diego Today. When these micronuclei rupture, the exposed DNA becomes vulnerable to nucleases, with N4BP2 uniquely capable of entering and fragmenting this genetic material.
-
Experimental validation by researchers at UC San Diego, including first author Ksenia Krupina, Ph.D., confirmed N4BP2's causal role in chromothripsis. Removing N4BP2 from brain cancer cells drastically reduced chromosome shattering, while inducing its presence in healthy cells caused intact chromosomes to break.
-
The study, published in Science, analyzed over 10,000 cancer genomes, revealing a strong correlation between heightened N4BP2 activity and increased chromothripsis, along with elevated levels of extrachromosomal DNA (ecDNA). EcDNA, known to carry cancer-promoting genes, is now understood to be a downstream consequence of N4BP2-driven chromothripsis.
-
Chromothripsis is surprisingly common, affecting approximately one in four human cancers, and is particularly prevalent in aggressive forms such as osteosarcomas and many brain cancers, as highlighted by News-Medical. This widespread occurrence underscores its critical role in tumor evolution and resistance.
-
Senior author Don Cleveland, Ph.D., a professor at UC San Diego School of Medicine, emphasized that this discovery provides a new and "actionable point of intervention" for slowing cancer evolution. Targeting N4BP2 or its associated pathways could limit the genomic instability that enables tumors to adapt, recur, and become drug-resistant.
-
This research aligns with broader efforts in cancer therapy to target DNA damage response (DDR) pathways, as discussed in a 2024 review. Exploiting vulnerabilities in DNA repair mechanisms, similar to the success of PARP inhibitors, offers promising strategies to improve treatment efficacy by making cancer cells more susceptible to damage.
-
Future research will likely focus on developing specific inhibitors for N4BP2 and exploring combination therapies to prevent rapid genetic adaptation in tumors. This could lead to novel treatment strategies for some of the most aggressive and treatment-resistant cancers, improving patient outcomes.
